PH 50E
Latest Information Update: 06 Feb 2023
At a glance
- Originator Pherin Pharmaceuticals
- Developer Janssen L.P.; Pherin Pharmaceuticals
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 02 Feb 2023 Pherin Pharmaceuticals has been acquired by VistaGen Therapeutics
- 09 Dec 2003 No development reported - Preclinical for Anxiety disorders in USA (Intranasal)
- 15 Nov 2000 New profile